Sage Potash Grants Stock Options


Werte in diesem Artikel

VANCOUVER, BC, June 7, 2024 /CNW/ - Sage Potash Corp., (TSXV: SAGE) (OTC: SGPTF) ("Sage" or the "Company") has granted an aggregate of 500,000 stock options to certain directors, officers, employees and consultants pursuant to the Company's stock option plan. The stock options have an exercise price of $0.295 per share and an expiry date of June 6, 2027.

Sage Potash Corp. logo (CNW Group/Sage Potash Corp.)

About Sage Potash Corp.

Sage Potash is a Canadian company vested solely in the Sage Plain Property and intends through sustainable solution mining techniques to become a prominent domestic potash producer within the Paradox Basin situated in Utah. For further information, please refer to the Company's disclosure record on SEDAR (www.sedar.com) or contact the Company by email at info@sagepotash.com. 

On Behalf of the Board of Directors,

Peter Hogendoorn
CEO & Executive Chairman
(604) 764-2158
Website: www.sagepotash.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain "forward-looking statements", which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward–looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sage-potash-grants-stock-options-302167138.html

SOURCE Sage Potash Corp.

Werbung

Sage Therapeutics Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sage Therapeutics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
14.12.18 Sage Therapeutics Outperform Wolfe Research
11.10.18 Sage Therapeutics Outperform Oppenheimer & Co. Inc.
07.08.18 Sage Therapeutics Buy Stifel, Nicolaus & Co., Inc.
26.03.18 Sage Therapeutics Buy Canaccord Adams
08.12.17 Sage Therapeutics Buy Needham & Company, LLC

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.